Clinical Research and Development Leaders
Arch Biopartners Scientific Team
Dr. Daniel Muruve MD
Chief Science Officer (CSO)
Co-Founder
Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from the Faculty of Medicine at the University of Manitoba in 1989 and has undertaken extensive post-graduate medical and scientific training over 10 years at the University of Calgary, Harvard University and the University of Lausanne. Dr. Muruve is a certified kidney specialist and a basic scientist with expertise in the biology of kidney disease and the molecular basis of inflammation and the immune system. He is an AHFMR Clinical Senior Scholar and holds a Canada Research Chair in Inflammation and Kidney Disease.
Dr. Justin Chun MD, Ph. D
Principal Scientist CKD Platform
Dr. Chun, MD, PhD, FASN is an Associate Professor and Royal College certified nephrologist at the Cumming School of Medicine, University of Calgary. He earned his MSc and PhD in Cell Biology from the University of Alberta, followed by clinical training in Internal Medicine and Nephrology at the University of Calgary. He then completed a postdoctoral research fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Chun serves as the Assistant Director of the Precision Medicine in Nephrology Program at the Snyder Institute for Chronic Diseases. He also co-directs the Human Organoid Innovation Hub, where his research focuses on the use of patient-derived kidney organoids and primary kidney cells to investigate glomerular diseases and diabetic kidney disease.
Dr. Arthur Lau Ph. D
Director of Clinical Trials and Research Scientist
Arthur Lau is the Director of Clinical Trials at Arch Biopartners and a Research Scientist in Dr. Daniel Muruve’s research program at the University of Calgary. He completed a B.Sc. with Honours at the University of Toronto and a Ph.D. at the University of Western Ontario with a focus on kidney transplantation and immunology. As a postdoctoral fellow at the University of Calgary under the mentorship of Dr. Muruve, he continued his research on acute kidney injury and immunology including publications describing the use of LSALT peptide in renal disease. His current research focus is on elucidating mechanisms of immune surveillance in the kidney and developing therapeutics against acute kidney injury. Arthur joined the Arch Biopartners’ team as a Project Manager primarily managing the development of the LSALT peptide/Metablok portfolio and its related technologies.
Dr. Justin Macdonald Ph. D
LEAD Scientist LSALT PEPTIDE & TREATMENTS FOR ORGAN INFLAMMATION
Justin Macdonald is a Professor in the Department of Biochemistry & Molecular Biology at the University of Calgary. He obtained his Ph.D. at Carleton University and his post-doctoral training at the University of Virginia and Duke University. His expertise is in smooth muscle contractile physiology, biochemistry and proteomics. He currently holds a Canada Research Chair in Smooth Muscle Pathophysiology.
Dr. Stephen Robbins Ph. D
LEAD Scientist LSALT PEPTIDE & TREATMENTS FOR ORGAN INFLAMMATION
Dr. Robbins is currently a Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular Biology. He is a former Canada Research Chair in Cancer Biology, and is an AHFMR Scientist. Dr. Robbins obtained his Ph. D from the University of British Columbia in 1991 and pursued postdoctoral training at the University of California, San Francisco, under the mentorship of Nobel Laureate Dr. J. Michael Bishop. His current research interests are in the area of developing novel therapeutics for cancer with a specific focus on brain tumours.
Dr. Donna Senger Ph. D
LEAD Scientist LSALT PEPTIDE & TREATMENTS FOR ORGAN INFLAMMATION
Dr. Senger obtained her PhD in the Department of Cell Biology at the University of Alberta. During her Ph. D studies she published a seminal paper in her field that described a novel signaling process in sympathetic neurons where nerve growth factor (NGF) induces a rapidly propagated signal that does not require vesicular transport of NGF. In 2000, Dr. Senger moved to the University of Calgary where she helped to establish a multi-disciplinary translational research group. Dr. Senger’s research has focused on numerous aspects of both primary and metastatic brain cancer with an emphasis on understanding brain tumour progression for the development of new treatments.
